IL263486B - Co-crystals of lithium benzoate and their uses - Google Patents
Co-crystals of lithium benzoate and their usesInfo
- Publication number
- IL263486B IL263486B IL263486A IL26348618A IL263486B IL 263486 B IL263486 B IL 263486B IL 263486 A IL263486 A IL 263486A IL 26348618 A IL26348618 A IL 26348618A IL 263486 B IL263486 B IL 263486B
- Authority
- IL
- Israel
- Prior art keywords
- crystals
- lithium benzoate
- benzoate
- lithium
- Prior art date
Links
- 239000013078 crystal Substances 0.000 title 1
- 229940031993 lithium benzoate Drugs 0.000 title 1
- LDJNSLOKTFFLSL-UHFFFAOYSA-M lithium;benzoate Chemical compound [Li+].[O-]C(=O)C1=CC=CC=C1 LDJNSLOKTFFLSL-UHFFFAOYSA-M 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C215/48—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups
- C07C215/54—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/03—Monocarboxylic acids
- C07C57/10—Sorbic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/30—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings
- C07C57/42—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings having unsaturation outside the rings
- C07C57/44—Cinnamic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C63/00—Compounds having carboxyl groups bound to a carbon atoms of six-membered aromatic rings
- C07C63/04—Monocyclic monocarboxylic acids
- C07C63/06—Benzoic acid
- C07C63/08—Salts thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
- C07D213/80—Acids; Esters in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Inorganic Chemistry (AREA)
- Emergency Medicine (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662349582P | 2016-06-13 | 2016-06-13 | |
| PCT/CN2017/088044 WO2017215592A1 (en) | 2016-06-13 | 2017-06-13 | Co-crystals of lithium benzoate and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL263486A IL263486A (en) | 2019-01-31 |
| IL263486B true IL263486B (en) | 2021-08-31 |
Family
ID=60663075
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL263486A IL263486B (en) | 2016-06-13 | 2018-12-04 | Co-crystals of lithium benzoate and their uses |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US10815184B2 (OSRAM) |
| EP (1) | EP3468946A4 (OSRAM) |
| JP (1) | JP6958923B2 (OSRAM) |
| KR (2) | KR102488927B1 (OSRAM) |
| CN (1) | CN109563024B (OSRAM) |
| CA (1) | CA3027300C (OSRAM) |
| IL (1) | IL263486B (OSRAM) |
| MX (1) | MX2018015463A (OSRAM) |
| RU (2) | RU2022101542A (OSRAM) |
| TW (1) | TWI736635B (OSRAM) |
| WO (1) | WO2017215592A1 (OSRAM) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2936094T3 (es) * | 2016-06-13 | 2023-03-14 | Syneurx Int Taiwan Corp | Cocristales de benzoato de sodio y usos de los mismos |
| WO2021245697A1 (en) | 2020-06-01 | 2021-12-09 | Celagenex Research (India) Pvt. Ltd. | Novel synergistic medicinal compositions for treating dysfunctional d-serine signaling |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3498989A (en) | 1969-04-16 | 1970-03-03 | American Home Prod | Certain 8-substituted-2-alkyl-3-benzoyl esters of ecgonine and derivatives thereof |
| US3870715A (en) | 1972-03-09 | 1975-03-11 | Nikolaus R Hansl | Substituted amino ethyl meta benzoic acid esters |
| US4041174A (en) | 1974-08-16 | 1977-08-09 | Rom-Amer Pharmaceuticals, Ltd. | Method of treating depression |
| US5204356A (en) | 1985-07-24 | 1993-04-20 | Glaxo Group Limited | Treatment of anxiety |
| US6150354A (en) | 1987-01-15 | 2000-11-21 | Bonnie Davis | Compounds for the treatment of Alzheimer's disease |
| GB8819494D0 (en) | 1988-08-16 | 1988-09-21 | Ucb Sa | Use of 2-amino-4-morpholino-6-propyl-1 3 5-triazines for preparation of psychotropic medicaments |
| US6746678B1 (en) | 1991-02-22 | 2004-06-08 | Howard K. Shapiro | Method of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with medicaments |
| WO1992014456A1 (en) | 1991-02-22 | 1992-09-03 | Shapiro Howard K | Use of pharmaceutical compounds in the treatment of symptoms of disorders related to neurological diseases and etiologically related symptomology |
| FR2700117B1 (fr) | 1993-01-07 | 1995-02-03 | Rhone Poulenc Rorer Sa | Application d'anticonvulsivants dans le traitement de la maladie de Parkinson et des syndromes parkinsoniens. |
| DE4340273A1 (de) | 1993-11-26 | 1995-06-01 | Karla Dr Lehmann | Arzneimittel zur Prophylaxe des Morbus Alzheimer und zur Verhütung des Fortschreitens dieser Erkrankung |
| US5453425A (en) | 1994-07-11 | 1995-09-26 | Janssen Pharmaceutica N.V. | Risperidone oral formulation |
| WO2001041707A2 (en) | 1999-12-08 | 2001-06-14 | Vanderbilt University | Modulation of in vivo glutamine and glycine levels in the treatment of autism |
| PT1783118E (pt) | 2000-08-14 | 2008-08-19 | Teva Pharma | Preparação de risperidona |
| US20030185754A1 (en) | 2001-01-16 | 2003-10-02 | Genset, S.A. | Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists |
| MXPA03006321A (es) | 2001-01-16 | 2003-10-06 | Genset Sa | Tratamiento de trastornos del sistema nervioso central usando antagonistas de d-aminoacido oxidasa y d-aspartato oxidasa. |
| US7927613B2 (en) | 2002-02-15 | 2011-04-19 | University Of South Florida | Pharmaceutical co-crystal compositions |
| US20070053976A1 (en) | 2002-05-17 | 2007-03-08 | Eisai R & D Management Co., Ltd. | Novel combination of drugs as antidepressant |
| US7053122B2 (en) | 2002-08-09 | 2006-05-30 | Pfizer Inc | Therapeutic use of aryl amino acid derivatives |
| US7273889B2 (en) | 2002-09-25 | 2007-09-25 | Innovative Drug Delivery Systems, Inc. | NMDA receptor antagonist formulation with reduced neurotoxicity |
| AU2003274353B2 (en) | 2002-10-24 | 2007-04-05 | Merz Pharma Gmbh & Co. Kgaa | Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors |
| WO2004065348A1 (en) | 2003-01-23 | 2004-08-05 | Pfizer Products Inc. | Pharmaceutically acceptable salts of sertraline and pharmaceutical compositions thereof |
| EP1628660A4 (en) | 2003-06-02 | 2010-06-02 | Samaritan Pharmaceuticals Inc | METHOD AND COMPOSITIONS FOR MODULATING THE CORTISOL SERUM MIRRORS |
| ZA200605384B (en) | 2003-12-29 | 2007-10-31 | Sepracor Inc | Benzo[D]isoxazol-3-OL DAAO inhibitors |
| EP1709053B1 (en) | 2004-01-27 | 2011-04-06 | Synthon B.V. | Stable salts of olanzapine |
| ATE454140T1 (de) | 2004-02-18 | 2010-01-15 | Sepracor Inc | Dopamin-agonisten-kombinationstherapie mit sedativa zur verbesserung der schlafqualität |
| KR20070009671A (ko) | 2004-05-06 | 2007-01-18 | 사이덱스 인크 | 세르트랄린 및 술포알킬 에테르 시클로덱스트린을 함유하는맛 마스킹된 제제 |
| EP1765379A4 (en) | 2004-06-17 | 2009-05-27 | Transform Pharmaceuticals Inc | PHARMACEUTICAL CO-CRYSTAL COMPOSITIONS AND RELEVANT USE METHOD |
| WO2006096439A2 (en) | 2005-03-04 | 2006-09-14 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases |
| CA2505808A1 (en) * | 2005-05-02 | 2006-11-02 | Julie Danielle Globus | Niacin used as oral supplementation for the treatment of psychosis and/or schizophrenia in humans |
| WO2006129160A2 (en) | 2005-06-01 | 2006-12-07 | Aurobindo Pharma Limited | Stable aqueous oral solution of risperidone |
| US20110045065A1 (en) | 2005-07-11 | 2011-02-24 | Ashok Vasantray Vyas | Substance having antioxidant, geroprotective and anti-ischemic activity and method for the preparation thereof |
| US7811604B1 (en) | 2005-11-14 | 2010-10-12 | Barr Laboratories, Inc. | Non-effervescent, orally disintegrating solid pharmaceutical dosage forms comprising clozapine and methods of making and using the same |
| GB0603181D0 (en) | 2006-02-17 | 2006-03-29 | Merck Sharp & Dohme | Treatment of neurodegenerative and psychiatric diseases |
| US20080045512A1 (en) | 2006-08-09 | 2008-02-21 | Pfizer Inc. | Benzoate salt of 4-(5-methyl-oxazolo[4,5-b]-pyridin-2-yl)-1,4-diazabicyclo[3.2.2]nonane |
| WO2008034087A2 (en) | 2006-09-15 | 2008-03-20 | Xenoport, Inc. | Treating schizophrenia with combinations of levodopa and an antipsychotic agent |
| US8071143B2 (en) * | 2008-04-02 | 2011-12-06 | Brandeis University | Methods for the treatment or prevention of diabetes mellitus and other metabolic imbalances |
| WO2010005581A1 (en) * | 2008-07-11 | 2010-01-14 | Kareus Therapeutics, Llc | Niacin compositions for reduction of amyloid beta peptide 42 (abeta 42) production and for treatment of alzheimer's disease (ad) |
| US20130338199A1 (en) | 2008-07-11 | 2013-12-19 | Uday Saxena | Novel Niacin Compositions for Reduction of Amyloid Beta Peptide 42 (AB42) Production and for Treatment of Alzheimer's Disease |
| GB0813709D0 (en) * | 2008-07-26 | 2008-09-03 | Univ Dundee | Method and product |
| JP2010106001A (ja) * | 2008-10-31 | 2010-05-13 | Theravalues Corp | Ｐｐａｒ活性化剤 |
| CN102292094B (zh) | 2009-01-20 | 2013-08-14 | 洛杉矶生物医学研究所在哈伯-加州大学洛杉矶分校医疗中心 | 增强神经药方疗效的山梨酸与苯甲酸及其衍生物 |
| EP3650439B1 (en) * | 2010-07-23 | 2021-02-24 | Grünenthal GmbH | Salts or co-crystals of 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol |
| JP2014508814A (ja) * | 2011-03-24 | 2014-04-10 | ユニバーシティ・オブ・サウス・フロリダ | リチウム組成物 |
| US9035044B2 (en) * | 2011-05-09 | 2015-05-19 | Janssen Pharmaceutica Nv | L-proline and citric acid co-crystals of (2S, 3R, 4R, 5S,6R)-2-(3-((5-(4-fluorophenyl)thiopen-2-yl)methyl)4-methylphenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol |
| US9120766B2 (en) * | 2011-10-21 | 2015-09-01 | Amri Ssci, Llc | Methods of making cocrystals |
| SI2986618T1 (sl) * | 2013-04-19 | 2022-08-31 | University of South Florida, Division of Patents and Licensing, | Organske anionske litijeve ionske kokristalne spojine in sestavki |
| EP2991999B1 (en) | 2013-04-29 | 2019-05-08 | Mapi Pharma Limited | Dapagliflozin lactose co-crystal |
| ES2788866T3 (es) * | 2013-12-13 | 2020-10-23 | Conaris Res Institute Ag | Una composición farmacéutica que contiene ácido nicotínico y/o nicotinamida para su uso en influir beneficiosamente en los niveles de lípidos en sangre mediante la modificación de la microbiota intestinal |
| JP2016517866A (ja) * | 2014-03-24 | 2016-06-20 | カオシュン・チャン・グン・メモリアル・ホスピタル | 認知症または軽度認知障害を予防または治療する組成物を製造するための安息香酸塩の使用 |
| CN103992320A (zh) * | 2014-05-26 | 2014-08-20 | 南京工业大学 | 一种混悬结晶制备药物共晶的方法 |
| US20170354666A1 (en) * | 2014-11-19 | 2017-12-14 | Rush University Medical Center | Compositions and methods for treating lysosomal disorders |
| RU2582962C1 (ru) | 2014-12-23 | 2016-04-27 | Ольга Алексеевна Громова | Средство для профилактики и лечения нейродегенеративной патологии и сосудистой деменции (варианты) |
| ES2936094T3 (es) | 2016-06-13 | 2023-03-14 | Syneurx Int Taiwan Corp | Cocristales de benzoato de sodio y usos de los mismos |
-
2017
- 2017-06-13 CA CA3027300A patent/CA3027300C/en active Active
- 2017-06-13 MX MX2018015463A patent/MX2018015463A/es unknown
- 2017-06-13 WO PCT/CN2017/088044 patent/WO2017215592A1/en not_active Ceased
- 2017-06-13 US US16/309,370 patent/US10815184B2/en active Active
- 2017-06-13 JP JP2018564930A patent/JP6958923B2/ja active Active
- 2017-06-13 EP EP17812703.1A patent/EP3468946A4/en active Pending
- 2017-06-13 TW TW106119578A patent/TWI736635B/zh active
- 2017-06-13 CN CN201780047178.3A patent/CN109563024B/zh active Active
- 2017-06-13 KR KR1020217037292A patent/KR102488927B1/ko active Active
- 2017-06-13 RU RU2022101542A patent/RU2022101542A/ru unknown
- 2017-06-13 KR KR1020197000865A patent/KR102338171B1/ko active Active
- 2017-06-13 RU RU2018146423A patent/RU2765625C2/ru active
-
2018
- 2018-12-04 IL IL263486A patent/IL263486B/en unknown
-
2020
- 2020-09-23 US US17/030,222 patent/US11739046B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA3027300C (en) | 2023-08-08 |
| MX2018015463A (es) | 2019-05-27 |
| CN109563024B (zh) | 2023-06-06 |
| CA3027300A1 (en) | 2017-12-21 |
| US20190177261A1 (en) | 2019-06-13 |
| JP2019518757A (ja) | 2019-07-04 |
| TW201811321A (zh) | 2018-04-01 |
| WO2017215592A1 (en) | 2017-12-21 |
| US10815184B2 (en) | 2020-10-27 |
| EP3468946A4 (en) | 2020-02-12 |
| IL263486A (en) | 2019-01-31 |
| RU2765625C2 (ru) | 2022-02-01 |
| JP6958923B2 (ja) | 2021-11-02 |
| TWI736635B (zh) | 2021-08-21 |
| US20210107856A1 (en) | 2021-04-15 |
| KR102338171B1 (ko) | 2021-12-09 |
| RU2022101542A (ru) | 2022-02-03 |
| RU2018146423A (ru) | 2020-07-14 |
| RU2018146423A3 (OSRAM) | 2020-10-06 |
| KR102488927B1 (ko) | 2023-01-13 |
| KR20190017939A (ko) | 2019-02-20 |
| KR20210142769A (ko) | 2021-11-25 |
| US11739046B2 (en) | 2023-08-29 |
| CN109563024A (zh) | 2019-04-02 |
| EP3468946A1 (en) | 2019-04-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL286316A (en) | New micro-dystrophins and related method of use | |
| IL250415B (en) | Antibodies against pd-l and methods of using them | |
| HUE046000T2 (hu) | Antiproferatív vegyületek és alkalmazásuk módszerei | |
| IL254655B (en) | Ibrutinib co-crystal | |
| ZA201702545B (en) | Neuroactive compounds and methods of use thereof | |
| IL284236A (en) | Modifications and uses of conotoxin peptides | |
| SI3218005T1 (sl) | Z glikanom delujoče spojine, in postopki uporabe | |
| HUE050761T2 (hu) | Vegyületek és alkalmazási eljárások | |
| GB201501583D0 (en) | Uses of co-crystals | |
| DK3233066T3 (da) | Orlistat- og acarbosepræparat med modificeret frigivelse til behand-ling af obesitas og relaterede metaboliske lidelser | |
| ZA201804228B (en) | Cftr regulators and methods of use thereof | |
| IL253204A0 (en) | Trifluoroacethydrazide compound, method for its preparation and use for preparing a medical preparation | |
| ZA201804230B (en) | Cftr regulators and methods of use thereof | |
| IL263492B (en) | Co-crystals of sodium benzoate and their uses | |
| ZA201606450B (en) | Compounds and their methods of use | |
| IL263486B (en) | Co-crystals of lithium benzoate and their uses | |
| ZA201804229B (en) | Cftr regulators and methods of use thereof | |
| HK40006891A (en) | Co-crystals of lithium benzoate and uses thereof | |
| GB201403697D0 (en) | Compounds and methods of use | |
| HK40006889A (en) | Co-crystals of sodium benzoate and uses thereof | |
| PT3377478T (pt) | Co-cristais de bilastina | |
| GB201401291D0 (en) | Bernard's theory of universal architecture and constructivism | |
| GB201401314D0 (en) | Bernard's theory of software and technology |